Synthetic Biologics, a biologics and drug development company, has announced its second quarter financial results. Here are three things to know about the company and its financial performance. 1. The ...

Synthetic Biologics has formed a clinical advisory board to support development of SYN-004, its lead anti-infective product candidate for the prevention of the effects of Clostridium difficile. The ...

Synthetic Biologics, a clinical stage company developing therapeutics to protect the gut microbiome, named Isaac J. Bright, MD, vice president, corporate development. 1. Dr. Bright will be responsible ...

Synthetic Biologics is teaming up with gut microbiome specialists Enterome Bioscience to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora of ...

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (SYN) (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas ...

ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of ...

-The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) - ...

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of ...

Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Synthetic Biologics Inc., an Ann Arbor, Mich.-based biotech ...